LY 2624803

Drug Profile

LY 2624803

Alternative Names: HY 10275; LY2624803

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Sleep disorder therapies
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H1 receptor antagonists; Serotonin 2A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Insomnia

Most Recent Events

  • 24 Jan 2011 Discontinued - Phase-I for Insomnia in United Kingdom (PO)
  • 24 Jan 2011 Discontinued - Phase-II for Insomnia in USA (PO)
  • 14 May 2010 Eli Lilly completes a phase I trial in Insomnia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top